Exposure-Response (E-R) Analysis of Progression Free Survival (PFS) for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma

被引：0
|
作者：
Feng, Yan [1 ]
Wang, Xiaoning [1 ]
Statkevich, Paul [1 ]
Roy, Amit [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
T-56
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [21] PROGRESSION-FREE SURVIVAL (PFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN PREVIOUSLY UNTREATED ADVANCED MELANOMA: A CORRELATION META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS)
    Leung, L.
    Chou, E.
    Kurt, M.
    Moshyk, A.
    Hamilton, M.
    Pourrahmat, M. M.
    Kanters, S.
    VALUE IN HEALTH, 2022, 25 (01) : S22 - S22
  • [22] TIME DEPENDENT PK OF PEMBROLIZUMAB AND IMPLICATION IN EXPOSURE-RESPONSE (E-R) ANALYSIS.
    Li, H.
    Yu, J.
    Liu, C.
    Wang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S73 - S73
  • [23] Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
    Sznol, Mario
    Ferrucci, Pier Francesco
    Hogg, David
    Atkins, Michael B.
    Wolter, Pascal
    Guidoboni, Massimo
    Lebbe, Celeste
    Kirkwood, John M.
    Schachter, Jacob
    Daniels, Gregory A.
    Hassel, Jessica
    Cebon, Jonathan
    Gerritsen, Winald
    Atkinson, Victoria
    Thomas, Luc
    McCaffrey, John
    Power, Derek
    Walker, Dana
    Bhore, Rafia
    Jiang, Joel
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3815 - +
  • [24] Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067
    Hodi, F. Stephen
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, Charles Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Queirolo, Paola
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew Graham
    Marquez-Rodas, Ivan
    Ritchings, Corey
    Sakkal, Leon A.
    Wang, Peter
    Wolchok, Jedd D.
    Larkin, James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] CLINICAL RESPONSE, PROGRESSION-FREE SURVIVAL (PFS) AND SAFETY IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) RECEIVING NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN CHECKMATE 069 STUDY
    Hodi, F. Stephen
    Postow, Michael A.
    Chesney, Jason
    Pavlik, Anna C.
    Robert, Caroline
    Grossman, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 109 - 109
  • [26] Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
    Uhara, Hisashi
    Kiyohara, Yoshio
    Uehara, Jiro
    Fujisawa, Yasuhiro
    Takenouchi, Tatsuya
    Otsuka, Masaki
    Uchi, Hiroshi
    Fukushima, Satoshi
    Minami, Hironobu
    Hatsumichi, Masahiro
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2021, 48 (05): : 592 - 599
  • [27] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma
    Kiyohara, Y.
    Takenouchi, T.
    Uhara, H.
    Koga, H.
    Uchi, H.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] EXPOSURE-RESPONSE (E-R) OF DUPILUMAB IN PEDIATRIC PATIENTS WITH MODERATE-TO-SEVERE ASTHMA.
    Xu, C.
    Sheng, T.
    Gao, Y.
    Kamal, M.
    Hardin, M.
    Meng, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S35 - S35
  • [29] Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew Hiram
    Ott, Patrick Alexander
    Horak, Christine E.
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)
    Lu, Ming
    Deng, Chenhui
    Xiong, Yifeng
    Wang, Hengbang
    Xu, Ping
    Men, Lichuang
    Xie, Tanhong
    Jiang, Qian
    Chen, Zi
    Niu, Qian
    Liu, Ping
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2020, 136
12345